Welcome to our dedicated page for Bio Green Med Solution SEC filings (Ticker: BGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Bio Green Med Solution, Inc. (BGMS) brings together the company’s official reports to the U.S. Securities and Exchange Commission, including Form 8-K current reports and other key documents. These filings describe how the company has transitioned from its former identity as Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, to a diversified business focused primarily on fire safety protection and distribution activities anchored by its acquisition of FITTERS Sdn. Bhd. in Malaysia.
Through its 8-K filings, Bio Green Med Solution, Inc. discloses material events such as the completion of the FITTERS Sdn. Bhd. share exchange transaction, the Asset Purchase Agreement with Tethra Biosciences Inc. for the sale of patent rights related to plogosertib, and the liquidation of its UK subsidiary, Cyclacel Limited. These documents also cover capital markets actions, including a one-for-fifteen reverse stock split of its common stock, Warrant Exchange Agreements that exchanged existing warrants for new common shares, and a Nasdaq notice regarding the minimum Market Value of Publicly Held Shares requirement for its 6% Convertible Exchangeable Preferred Stock (BGMSP).
Filings further address governance and compensation matters, such as the resignation and appointment of independent directors, committee assignments for the Audit, Compensation and Organization, and Nominating and Governance Committees, and confirmation of director independence and financial literacy under SEC and Nasdaq standards. Dividend declarations on the company’s 6% Convertible Exchangeable Preferred Stock are also documented in Form 8-K reports.
On this page, users can access Bio Green Med Solution, Inc.’s SEC filings as they are made available from EDGAR and review AI-generated summaries that explain the main points of lengthy documents, including 10-K annual reports, 10-Q quarterly reports, and Form 4 insider transaction reports where applicable. These tools help readers quickly understand complex regulatory disclosures, track changes in the company’s business focus, and follow developments affecting its common and preferred equity securities.
Bio Green Med Solution (BGMS) insider activity: Reporting person Kua Khai Loon, a director, filed a Form 4 disclosing open-market sales of BGMS common stock. On 10/15/2025, 7,479 shares were sold at $5.661, leaving 330,681 shares beneficially owned. On 10/16/2025, 88,204 shares were sold at $4.217, leaving 242,477 shares beneficially owned. Ownership is listed as Direct. The filing was made by one reporting person.
Bio Green Med Solution (BGMS) Form 4: A reporting person identified as a 10% owner reported a sale of common stock. On 10/16/2025, the holder sold 26,051 shares (transaction code S) at a price of $5.50 per share. Following this transaction, the filer beneficially owned 479,707 shares, held directly.
Bio Green Med Solution (BGMS): A reporting person filed a Form 4 showing an open‑market sale of common stock. On 10/14/2025, the filer sold 135,793 shares at $6 per share (Transaction Code S). Following the transaction, the filer reported 268,672 shares beneficially owned with direct ownership.
Bio Green Med Solution (BGMS) reported an insider transaction on a Form 4. A 10% owner sold 51,400 shares of common stock on 10/10/2025 at $5.258 per share (Transaction Code: S). Following the sale, the reporting person beneficially owned 505,758 shares, held directly. The filing was made by /s/ Datuk Tan Chor How Christopher on 10/14/2025.
Report overview: This Schedule 13G/A states that Kua Khai Loon beneficially owns 805,695 shares of Bio Green Med Solution, Inc. common stock, representing 16.35% of the class. The filing breaks ownership into 338,160 common shares and warrants totaling 467,535 (218,000 Series A warrants, 218,000 Series B warrants, and 31,535 Series C warrants) that are exercisable into common stock.
The filer certifies the shares were not acquired to change or influence control. The document lists the issuer's Kuala Lumpur address and the reporter's Malaysian residence, and it attaches warrant forms as exhibits.
Bio Green Med Solution (BGMS) filed a Form 4 reporting insider stock sales by Kua Khai Loon, a Director. On 09/12/2025, the insider sold 22,251 shares of common stock at $6.224 per share, leaving 363,160 shares beneficially owned. On 09/16/2025, the insider sold an additional 25,000 shares at $5.132 per share, with 338,160 shares beneficially owned afterward. Both positions are listed as Direct (D) ownership.
FITTERS Diversified Berhad, a director, reported a sale of
Bio Green Med Solution, Inc. reported that its Board of Directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on November 1, 2025 to holders of the Preferred Stock who are on record as of the close of business on October 20, 2025.
FAQ
What is the current stock price of Bio Green Med Solution (BGMS)?
What is the market cap of Bio Green Med Solution (BGMS)?
